Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

NCT05404139 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

132

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Prostate Cancer

Interventions

DRUG: Enzalutamide
OTHER: Standard of Care SBRT and ADT

Sponsor

University Health Network, Toronto

Collaborators

[object Object]